InterMune Likely First To Market In IPF, But Other Firms Poised To Follow

With an FDA advisory committee recommendation for approval and a May 4 PDUFA date, InterMune holds a significant lead over the rest of the field and should be first to market with a drug to treat idiopathic pulmonary fibrosis